SecBot SecBot
SECBOTREPLAY Home › Report › ADCT

ADCT · Q3 revenue +33% YoY

ADC Therapeutics SA · 8-K filed Nov 9, 2026 at 08:06 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Nov 9, 2026 at 08:06 ET

ADC Therapeutics reported Q3 2026 net product revenue of $21.0M, up 33% YoY from $15.8M, and a GAAP net loss of $0.16 per share, narrowing from a $0.30 loss a year ago. The company highlighted a strategic financial restructuring that included an $86.6M PIPE, debt reduction, and an extended cash runway into 2029, alongside upcoming ASH presentations for ZYNLONTA.

  • Q3 2026 net product revenue was $21.0M, up from $15.8M in Q3 2025, a 33% increase.
  • GAAP net loss per share was $0.16, compared to $0.30 in Q3 2025.
  • Adjusted net loss per share was $0.06, compared to $0.19 in Q3 2025.
  • Cash and cash equivalents were $189.2M as of September 30, 2026, with expected cash runway into 2029.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access